Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2'-c-cyano-2'-deoxy-1-arabinofuranosyl-n(4)-palmitoylcytosine
2. Cndac Cpd
3. Cs-682
4. Cyc 682
5. Cyc-682
1. 151823-14-2
2. Cs-682
3. Cyc682
4. Cyc-682
5. Cs682
6. Cs 682
7. Pcndac
8. Cyc 682
9. W335p73c3l
10. N-(1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl)hexadecanamide
11. N-(1-((2r,3s,4s,5r)-3-cyano-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)palmitamide
12. Sapacitabine [usan:inn]
13. Sapacitabina
14. Sapacitabinum
15. Unii-w335p73c3l
16. Sapacitabine (cyc682)
17. Sapacitabine (usan/inn)
18. Sapacitabine [inn]
19. Sapacitabine [usan]
20. Sapacitabine [mart.]
21. N-[1-[(2r,3s,4s,5r)-3-cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide
22. Sapacitabine [who-dd]
23. Schembl711854
24. Chembl2105681
25. Dtxsid90164887
26. Chebi:145429
27. Ex-a1617
28. Nsc791785
29. Zinc14263648
30. Db06365
31. Nsc-791785
32. Ac-36130
33. Hexadecanamide, N-(1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl)-
34. Hy-16445
35. Cs-0006340
36. D09722
37. 823s142
38. Q7420893
39. 2'-c-cyano-2'-deoxy-1-arabinofuranosyl-n(4)-palmitoylcytosine
40. 1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-4-(hexadecanoylamino)pyrimidin-2(1h)-one
41. Hexadecanamide, N-(1-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)-1,2-dihydro-2-oxo-4- Pyrimidinyl)-
42. N-(1-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4- Yl)hexadecanamide
43. N-[1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidine-4-yl]hexadecanamide
| Molecular Weight | 490.6 g/mol |
|---|---|
| Molecular Formula | C26H42N4O5 |
| XLogP3 | 5.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 17 |
| Exact Mass | 490.31552045 g/mol |
| Monoisotopic Mass | 490.31552045 g/mol |
| Topological Polar Surface Area | 135 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 775 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in solid tumors, cutaneous t-cell lymphoma, myelodysplastic syndrome, and leukemia (lymphoid).
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Sapacitabine appears to act through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drugs converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies.
ABOUT THIS PAGE
A Sapacitabine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sapacitabine, including repackagers and relabelers. The FDA regulates Sapacitabine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sapacitabine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sapacitabine supplier is an individual or a company that provides Sapacitabine active pharmaceutical ingredient (API) or Sapacitabine finished formulations upon request. The Sapacitabine suppliers may include Sapacitabine API manufacturers, exporters, distributors and traders.
click here to find a list of Sapacitabine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sapacitabine DMF (Drug Master File) is a document detailing the whole manufacturing process of Sapacitabine active pharmaceutical ingredient (API) in detail. Different forms of Sapacitabine DMFs exist exist since differing nations have different regulations, such as Sapacitabine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sapacitabine DMF submitted to regulatory agencies in the US is known as a USDMF. Sapacitabine USDMF includes data on Sapacitabine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sapacitabine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sapacitabine suppliers with USDMF on PharmaCompass.
Sapacitabine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sapacitabine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sapacitabine GMP manufacturer or Sapacitabine GMP API supplier for your needs.
A Sapacitabine CoA (Certificate of Analysis) is a formal document that attests to Sapacitabine's compliance with Sapacitabine specifications and serves as a tool for batch-level quality control.
Sapacitabine CoA mostly includes findings from lab analyses of a specific batch. For each Sapacitabine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sapacitabine may be tested according to a variety of international standards, such as European Pharmacopoeia (Sapacitabine EP), Sapacitabine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sapacitabine USP).
LOOKING FOR A SUPPLIER?
